225 related articles for article (PubMed ID: 22705990)
1. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?
Usmani SZ; Crowley J; Hoering A; Mitchell A; Waheed S; Nair B; AlSayed Y; Vanrhee F; Barlogie B
Leukemia; 2013 Jan; 27(1):226-32. PubMed ID: 22705990
[TBL] [Abstract][Full Text] [Related]
2. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
[TBL] [Abstract][Full Text] [Related]
3. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Zangari M; van Rhee F; Anaissie E; Pineda-Roman M; Haessler J; Crowley J; Barlogie B
Br J Haematol; 2008 May; 141(4):433-44. PubMed ID: 18371114
[TBL] [Abstract][Full Text] [Related]
4. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
Pineda-Roman M; Zangari M; Haessler J; Anaissie E; Tricot G; van Rhee F; Crowley J; Shaughnessy JD; Barlogie B
Br J Haematol; 2008 Mar; 140(6):625-34. PubMed ID: 18302711
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
6. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Barlogie B; Tricot G; Rasmussen E; Anaissie E; van Rhee F; Zangari M; Fassas A; Hollmig K; Pineda-Roman M; Shaughnessy J; Epstein J; Crowley J
Blood; 2006 Apr; 107(7):2633-8. PubMed ID: 16322468
[TBL] [Abstract][Full Text] [Related]
7. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.
Biran N; Jacobus S; Vesole DH; Callander NS; Fonseca R; Williams ME; Abonour R; Katz MS; Rajkumar SV; Greipp PR; Siegel DS
Blood Cancer J; 2016 Sep; 6(9):e466. PubMed ID: 27588519
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Barlogie B
Semin Hematol; 2003 Oct; 40(4 Suppl 4):33-8. PubMed ID: 15015894
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.
Barlogie B; Attal M; Crowley J; van Rhee F; Szymonifka J; Moreau P; Durie BG; Harousseau JL
J Clin Oncol; 2010 Mar; 28(7):1209-14. PubMed ID: 20085933
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
Rajkumar SV
Semin Hematol; 2003 Oct; 40(4 Suppl 4):17-22. PubMed ID: 15015892
[TBL] [Abstract][Full Text] [Related]
12. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
14. Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report.
An N; Li X; Shen M; Chen S; Huang Z
World J Surg Oncol; 2015 Aug; 13():239. PubMed ID: 26245342
[TBL] [Abstract][Full Text] [Related]
15. Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
Barlogie B; Haessler J; Pineda-Roman M; Anaissie E; van Rhee F; Kiwan E; Steward D; Gurley J; Jenkins B; Crowley J
Cancer; 2008 Jun; 112(12):2720-5. PubMed ID: 18433012
[TBL] [Abstract][Full Text] [Related]
16. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
Hoering A; Crowley J; Shaughnessy JD; Hollmig K; Alsayed Y; Szymonifka J; Waheed S; Nair B; van Rhee F; Anaissie E; Barlogie B
Blood; 2009 Aug; 114(7):1299-305. PubMed ID: 19515721
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
[TBL] [Abstract][Full Text] [Related]
19. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
[TBL] [Abstract][Full Text] [Related]
20. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
